tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Nerve Degeneration D009410 53 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Fatty Liver D005234 48 associated lipids
Precancerous Conditions D011230 48 associated lipids
Psoriasis D011565 47 associated lipids
Leukemia P388 D007941 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Uchida J et al. Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients. 2014 Transplant. Proc. pmid:24656005
Weng LC et al. Association between use of FK506 and prevalence of post-transplantation diabetes mellitus in kidney transplant patients. 2014 Transplant. Proc. pmid:24656004
Wang SS et al. Clinical experience of tacrolimus with everolimus in heart transplantation. 2012 Transplant. Proc. pmid:22564581
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Jain AB et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. 1990 Transplant. Proc. pmid:1689900
Fung JJ et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. 1990 Transplant. Proc. pmid:1689901
Stock PG et al. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. 1993 Transplant. Proc. pmid:7679838
Jain AB et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721270
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Sakr M et al. Effect of renal ischemia on plasma levels of FK 506 in rats. 1992 Transplant. Proc. pmid:1371625
Zervos XA et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplant. Proc. pmid:9636568
Tsang WK et al. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. 2000 Transplant. Proc. pmid:11119921
Stringa P et al. Ischemic preconditioning and tacrolimus pretreatment as strategies to attenuate intestinal ischemia-reperfusion injury in mice. 2013 Jul-Aug Transplant. Proc. pmid:23953566
Smit JA et al. Induction of primate TH2 lymphokines to suppress TH1 cells. 1996 Transplant. Proc. pmid:8623334
Osuna A et al. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age. 2005 Transplant. Proc. pmid:15866630
Pascual J et al. Interaction between omeprazole and tacrolimus in renal allograft recipients: a clinical-analytical study. 2005 Transplant. Proc. pmid:16386527
Garcia-Donaire JA et al. Tacrolimus as basic immunosuppression in pregnancy after renal transplantation. A single-center experience. 2005 Transplant. Proc. pmid:16386528
Argudo A et al. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. 2015 Transplant. Proc. pmid:26518936
Cuñetti L et al. Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. 2018 Transplant. Proc. pmid:29579828
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Kar S and Carr B Gene expression of FK 506-binding protein. 1991 Transplant. Proc. pmid:1721303
Burke GW et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. 1998 Transplant. Proc. pmid:9636627
Gruessner RW Antibody induction therapy in pancreas transplantation. 1998 Transplant. Proc. pmid:9636632
Moffatt SD et al. Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578277
Burg M et al. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. 2009 Transplant. Proc. pmid:20005359
Falkiewicz K et al. Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation. 2005 Transplant. Proc. pmid:15848611
Kantarci G et al. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. 2004 Jan-Feb Transplant. Proc. pmid:15013339
Yamazaki R et al. Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. 2009 Transplant. Proc. pmid:19545738
Platz KP et al. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation. 1997 Transplant. Proc. pmid:9365598
Gozdowska J et al. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience. 2011 Transplant. Proc. pmid:21996197
Platz KP et al. Indications for mycofenolate mofetil therapy after liver transplantation. 1997 Transplant. Proc. pmid:9365601
Shibutani S et al. FK 506 abrogates induction of regulatory cells after intratracheal delivery of alloantigen. 2002 Transplant. Proc. pmid:12176432
Lee TK et al. Bacterial translocation and the role of postoperative selective bowel decontamination in small intestinal transplantation. 1994 Transplant. Proc. pmid:7518154
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Tanaka M et al. Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. 1995 Transplant. Proc. pmid:7533392
Winkler M et al. Use of FK 506 for treatment of chronic rejection after liver transplantation. 1991 Transplant. Proc. pmid:1721334
Hasegawa A et al. Improvement of quality of life in tacrolimus-based pediatric renal transplant recipients and their caregivers, including donors. 2005 Transplant. Proc. pmid:15919461
Wilson C et al. Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial. 2005 Transplant. Proc. pmid:15919462
Tzakis AG et al. Campath-1H in intestinal and multivisceral transplantation: preliminary data. 2002 Transplant. Proc. pmid:12034248
Viganò J et al. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series. 2008 Jul-Aug Transplant. Proc. pmid:18675099
Ciftci HS et al. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism. 2017 Transplant. Proc. pmid:28340819
Rodrigues N et al. Serum Magnesium and Related Factors in Long-Term Renal Transplant Recipients: An Observational Study. 2017 Transplant. Proc. pmid:28457398
Woo J et al. FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. 1992 Transplant. Proc. pmid:1281583
Sasaki K et al. Effect of FK 506 and splenectomy on orthotopic small bowel xenotransplantation in the hamster-to-rat animal models. 1998 Transplant. Proc. pmid:9838521
Jabiry-Zieniewicz Z et al. Outcome of four high-risk pregnancies in female liver transplant recipients on tacrolimus immunosuppression. 2006 Jan-Feb Transplant. Proc. pmid:16504718
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Starzl TE et al. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. 1991 Transplant. Proc. pmid:1703351
Moreno JM et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. 2003 Transplant. Proc. pmid:12962831
Marino IR et al. Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. 1997 Feb-Mar Transplant. Proc. pmid:9123079
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Shapiro R et al. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. 2002 Transplant. Proc. pmid:12176521
Marcus EA et al. Successful term pregnancy in an intestine-pancreas transplant recipient with chronic graft dysfunction and parenteral nutrition dependence: a case report. 2015 Transplant. Proc. pmid:25724255
Townamchai N et al. A Simple Novel Technique to Estimate Tacrolimus Dosages During the Early Post Kidney Transplantation Period. 2015 Transplant. Proc. pmid:26518946
Masaki Y et al. Cellular basis of immunologic tolerance following total bowel transplantation in rats. II. Dominant role of suppressor T cells in adoptive transfer of acquired tolerance to vascularized allografts. 1995 Transplant. Proc. pmid:7536972
Suzuki H et al. Spleen grafting might induce transplantation tolerance in rats. 1995 Transplant. Proc. pmid:7536973
Jordán de Luna C et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. 2011 Jul-Aug Transplant. Proc. pmid:21839244
Klupp J et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083497
Castel MA et al. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine. 2011 Jul-Aug Transplant. Proc. pmid:21839245
Yang HC et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. 1999 Feb-Mar Transplant. Proc. pmid:10083501
Sakamoto K et al. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506. 1989 Transplant. Proc. pmid:2468222
Moutabarrik A et al. Use of FK 506 in kidney transplantation. 1993 Transplant. Proc. pmid:7685946
Bunnapradist S and Takemoto SK Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. 2003 Transplant. Proc. pmid:14611971
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Balbontin FG et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. 2003 Transplant. Proc. pmid:14611982
Saracino A et al. Multidrug-resistance 1 gene single-nucleotide polymorphisms do not influence long-term graft survival after kidney transplantation. 2014 Transplant. Proc. pmid:25242754
Alessiani M et al. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. 1997 Feb-Mar Transplant. Proc. pmid:9123483
Galvao FH et al. Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. 1997 Feb-Mar Transplant. Proc. pmid:9123488
Salizzoni M et al. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. 2001 Transplant. Proc. pmid:11377521
El Haggan W et al. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176589
Langrehr JM et al. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563. 2001 Transplant. Proc. pmid:11377531
Tanabe K et al. Prospective analysis of thrombotic microangiopathy after renal transplantation: comparison between cyclosporine and tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176590
Bhagavati S et al. Chronic sensorimotor polyneuropathy associated with tacrolimus immunosuppression in renal transplant patients: case reports. 2007 Transplant. Proc. pmid:18089409
Zaltzman J et al. Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267183
de Bruin RW et al. Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721429
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Goto T et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445072
Burrows L et al. Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients. 1998 Transplant. Proc. pmid:9723378
Fuchs U et al. Clinical outcome in cardiac transplant recipients receiving tacrolimus retard. 2013 Transplant. Proc. pmid:23769094
Koc-Zorawska E et al. Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients. 2013 Transplant. Proc. pmid:23769096
Rabkin JM et al. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267411
Uber PA et al. Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267428
Kim SH et al. Outcomes of Early Conversion From Prograf to Generic Tacrolimus in Adult Living Donor Liver Transplant Recipients. Transplant. Proc. pmid:26293073
Falconer SJ et al. Early or Late Conversion From Tac-BD to Tac-BD in Renal Transplantation: When is the Right Time? Transplant. Proc. pmid:26293044
Shi G et al. Variation of CD4CD25Foxp3 Regulatory T Cells and Th17 Cells in the Peripheral Blood of Human Liver Allograft Patients With Long-term Survival. 2017 Transplant. Proc. pmid:28923634
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
Isobe M et al. Downregulation of endothelin expression in allograft coronary arteries after gene therapy targeting Cdk2 kinase. 1998 Transplant. Proc. pmid:9636407
Duzova A et al. Triple immunosuppression with tacrolimus in pediatric renal transplantation: single-center experience. 2008 Jan-Feb Transplant. Proc. pmid:18261567
Blume C et al. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. 2001 Nov-Dec Transplant. Proc. pmid:11750357
Han SY et al. Effect of tacrolimus on the production of oxygen free radicals in hepatic mitochondria. 2006 Transplant. Proc. pmid:16980054
Jørgensen KA et al. Optimal time for determination of blood tacrolimus level. 2001 Nov-Dec Transplant. Proc. pmid:11750358
Deleuze S et al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? 2006 Transplant. Proc. pmid:16980075
Kuroki H et al. Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1703697
White SA et al. Effect of acute rejection on expression of fibrosis associated genes in renal transplant recipients. 2000 Transplant. Proc. pmid:10700949
Martins L et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? 2004 Transplant. Proc. pmid:15194300
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698
Busque S et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. 1998 Transplant. Proc. pmid:9636507
Braun F et al. Living-related versus living-unrelated kidney transplantation using tacrolimus initial immunosuppression. 2000 Transplant. Proc. pmid:10700989
Finni PE et al. Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus? 2004 Transplant. Proc. pmid:15194303
Loss GE et al. Reversal of delayed hyperacute renal allograft rejection with a tacrolimus-based therapeutic regimen. 1998 Transplant. Proc. pmid:9636508